These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 28529220)
1. Clinical Correlates of Treatment Response among Patients with Schizophrenia in a Tertiary Nigerian Hospital. Ezeme MS; Uwakwe R; Ndukuba AC; Igwe MN; Odinka PC; Amadi K; Obayi NO J Health Care Poor Underserved; 2017; 28(2):721-738. PubMed ID: 28529220 [TBL] [Abstract][Full Text] [Related]
2. Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria. Ezeme MS; Uwakwe R; Ndukuba AC; Igwe MN; Odinka PC; Amadi K; Obayi NO Afr Health Sci; 2016 Dec; 16(4):1036-1044. PubMed ID: 28479897 [TBL] [Abstract][Full Text] [Related]
3. [Relationships between insight and medication adherence in subjects with psychosis]. Droulout T; Liraud F; Verdoux H Encephale; 2003; 29(5):430-7. PubMed ID: 14615692 [TBL] [Abstract][Full Text] [Related]
4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986 [TBL] [Abstract][Full Text] [Related]
6. [Metabolic side effects of risperidone in early onset schizophrenia]. Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267 [TBL] [Abstract][Full Text] [Related]
7. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754 [TBL] [Abstract][Full Text] [Related]
8. Persistence in treatment for one year among patients in Nigeria with first-episode schizophrenia. Esan O Psychiatr Serv; 2014 Sep; 65(9):1174-6. PubMed ID: 25179189 [TBL] [Abstract][Full Text] [Related]
9. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Liu-Seifert H; Osuntokun OO; Feldman PD Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400 [TBL] [Abstract][Full Text] [Related]
10. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited. Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198 [TBL] [Abstract][Full Text] [Related]
11. Correlates of cognitive deficits in first episode schizophrenia. Heydebrand G; Weiser M; Rabinowitz J; Hoff AL; DeLisi LE; Csernansky JG Schizophr Res; 2004 May; 68(1):1-9. PubMed ID: 15037334 [TBL] [Abstract][Full Text] [Related]
12. Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia. Eticha T; Teklu A; Ali D; Solomon G; Alemayehu A PLoS One; 2015; 10(3):e0120560. PubMed ID: 25816353 [TBL] [Abstract][Full Text] [Related]
13. PREVALENCE AND PREDICTORS OF MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIA IN MAIDUGURI, NORTHEASTERN NIGERIA. Shettima F; Sheikh T; Wakil M; Wakama I; Abdulaziz M; Rabbebe I West Afr J Med; 2023 Nov; 40(11 Suppl 1):S21-S22. PubMed ID: 37976234 [TBL] [Abstract][Full Text] [Related]
14. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
15. Reliability and validity of the Medication Adherence Rating Scale in a cohort of patients with schizophrenia from Nigeria. Owie GO; Olotu SO; James BO Trends Psychiatry Psychother; 2018; 40(2):85-92. PubMed ID: 29768528 [TBL] [Abstract][Full Text] [Related]
16. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs. Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887 [TBL] [Abstract][Full Text] [Related]
17. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
18. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? Tollefson GD; Andersen SW J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404 [TBL] [Abstract][Full Text] [Related]
19. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758 [TBL] [Abstract][Full Text] [Related]
20. Treatment adherence and insight in schizophrenia. Bitter I; Fehér L; Tényi T; Czobor P Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]